Zhonghan Zhang
State Key Laboratory Of Oncology In South China
Guangzhou, 510060, China
Guangzhou, 510060, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications
FAK activation drives non-genetic adaptive survival of ALK-rearranged lung cancer under tyrosine kinase inhibitor treatment.
Journal: Journal of genetics and genomics = Yi chuan xue bao
Published: October 26, 2025
Diverse genomic and transcriptomic heterogeneity in EGFR-mutant lung adenocarcinoma between exon 19 del and exon 21 L858R.
Journal: Cell communication and signaling : CCS
Published: October 14, 2025
The assembly of RAB22A/TMEM33/RTN4 initiates a secretory ER-phagy pathway.
Journal: Cell discovery
Published: August 07, 2024
Activated STING-containing R-EVs from iPSC-derived MSCs promote antitumor immunity.
Journal: Cancer letters
Published: March 12, 2024
Influence of TP53 mutation on efficacy and survival in advanced EGFR-mutant non-small cell lung cancer patients treated with third-generation EGFR tyrosine kinase inhibitors.
Journal: MedComm
Published: September 14, 2023
Retraction Note: p300 promotes proliferation, migration, and invasion via inducing epithelial-mesenchymal transition in non-small cell lung cancer cells.
Journal: BMC cancer
Published: April 30, 2023
First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 06, 2021
Response to "Limitations of the Hazard Ratio as a Summary Measure in Cancer Clinical Trials".
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: August 08, 2021
Response to: The Role of Dual Inhibition of EGFR and Vascular EGF(R) in the Treatment of NSCLC With EGFR Mutation.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: July 17, 2021
Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer.
Journal: BMC medicine
Published: May 22, 2021
Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China.
Journal: Journal of hematology & oncology
Published: April 14, 2021
Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706).
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: March 08, 2021
Last Updated: 09/26/2026